By Michael Woodhead (via the Limbic)
A novel analgesic for osteoarthritis may offer better pain relief than current options but at the risk of more progressive disease and higher rates of total joint replacement.
Tanezumab, a monoclonal antibody blocking nerve growth factor, improved pain and physical function when compared to placebo in a trial of patients with moderate to severe OA of the knee or hip and inadequate response to standard analgesics.
But the 16-week randomised controlled trial involving 696 patients failed to dispel concerns from previous studies that tanezumab use was
associated with high rates of joint damage and total joint replacements.
Full Article available via The